Royce & Associates
ACHN

Royce & Associates’s Achillion Pharmaceuticals ACHN Stock Holding History

Royce & Associates’s Portfolio ACHN Stock Details ACHN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-2,262
Closed -$23K – 1413
2014
Q3 		$23K Hold
2,262
– – ﹤0.01% 1381
2014
Q2 		$17K Sell
2,262
-497,738
-100% -$1.99M ﹤0.01% 1411
2014
Q1 		$1.65M Sell
500,000
-90,000
-15% -$315K ﹤0.01% 1085
2013
Q4 		$1.96M Buy
+590,000
New +$1.71M 0.01% 1072

Other funds holding ACHN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RA Capital Management
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BlackRock Fund Advisors
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Janus Henderson Investors US
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
BCPEM
Bain Capital Public Equity Management Boston, Massachusetts $1.05B AUM 25.71% 1-Year Est. Return
Deerfield Management
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Royce & Associates's ACHN Position: Q4 2014 in Review

Royce & Associates sold out of Achillion Pharmaceuticals (ACHN) in Q4 2014, closing a stake of 2,262 shares — an estimated $23K sold.

Royce & Associates first reported a position in ACHN in Q4 2013 and held it in 4 quarters. The position peaked at $1.96M in Q4 2013. 179 funds tracked by Wall St. Rank hold ACHN as of Q4 2014.

  • Royce & Associates reported no remaining Achillion Pharmaceuticals position as of Q4 2014 after selling out during the quarter.
  • Royce & Associates sold 2,262 Achillion Pharmaceuticals shares in Q4 2014, an estimated $23K.
  • Royce & Associates first reported a position in Achillion Pharmaceuticals in Q4 2013 and held it in 4 quarters.
  • Royce & Associates's Achillion Pharmaceuticals position peaked at $1.96M in Q4 2013.
  • 179 funds tracked by Wall St. Rank held Achillion Pharmaceuticals as of Q4 2014.

Based on Royce & Associates's 13F filing for Q4 2014, filed 9 Feb 2015.